Think Bioscience
PrivateLast Round
Series A
Jan 20, 2026
Est. Valuation
$140.18M
Total Funding Raised
$81.15M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Think Bioscience operates in Healthcare & Life Sciences and is based in Boulder, Colorado. Its latest recorded funding round was a Series A round in January 2026.
Think Bioscience is a biotechnology company that develops small-molecule therapeutics for historically challenging drug targets using a proprietary synthetic biology platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Think Bioscience Comparables
Compare Think Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Octant | 81% | |
| Antares Therapeutics | 74% | |
| TRIANA Biomedicines | 74% |
For institutional investors. Book with your work email.
Think Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 20, 2026 | ||||
| Seed | May 7, 2024 | ||||
| Grant | Nov 25, 2022 | ||||
| Seed | Aug 18, 2022 | ||||
| Pre Seed | Sep 1, 2021 | ||||
Grant | Nov 19, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Think Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A |
| National Institute of Allergy and Infectious Diseases | Grant |
| Xora Innovation | Pre Seed, Seed |
| Wireframe Ventures | Pre Seed, Seed, Grant |
| Innovation Endeavors | Series A, Seed |
| CE-Ventures | Series A |
| Buff Gold Ventures | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 895% MoM, from 260 to 2.6K.
- Jan 20, 2026
$55M round completed.
For institutional investors. Book with your work email.
Think Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Think Bioscience's valuation, stock price, and market status.
Is Think Bioscience a public or private company?
Think Bioscience is a private company.
What is the current stock price of Think Bioscience?
Think Bioscience is a private company, so its shares have no public market price. Caplight tracks Think Bioscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Think Bioscience worth (valuation)?
Think Bioscience's valuation is estimated at $140.2M based on funding round data.
Can I buy Think Bioscience stock?
Think Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Think Bioscience's last funding round?
Think Bioscience's most recent funding round was Series A on January 20, 2026.
Who are the main investors in Think Bioscience?
Key investors in Think Bioscience include Janus Henderson Group, Xora Innovation, Innovation Endeavors.
Will Think Bioscience IPO soon?
No public IPO plans have been announced for Think Bioscience.
How can I track Think Bioscience secondary market activity?
Caplight tracks bids, offers, and trades in Think Bioscience's shares on secondary markets.